Vinehealth : Georgina Kirby, Co-Founder & CTO 

Patient behaviours are the single biggest driver of quality of life and outcomes in cancer; yet patients struggle to cope with the complexity of medication and lifestyle behaviours involved in managing cancer. Vine Health is a digital ecosystem that combines behavioural science & AI to optimise care and increase survival of cancer patients. In empowering patients, the Vine Health platform gathers real-world patient-generated data that is crucial to pharmaceutical drug development, licensing and reimbursement.

I ntrepid Analytics

We solve problems in healthcare using AI. Our patient-facing product, Ancora, helps patients search for, access and understand clinical trials (potentially saving lives). This reduces trial recruitment inefficiencies which currently cost sponsors $4.1B and delay 80% of trials.


FabricNano : Grant Aarons, CEO

FabricNano designs artificial cells that produce chemicals 100x faster, enabling manufacturers to scale output, reduce costs and discover new molecules.


Blazar : Dora Sabino, CEO

We are building a machine learning platform to predicit response to immunotherapies.


Nanovery : Mun Ching Lee, CEO

We are an AI-powered nanorobot platform for early cancer detection. We are building nanorobots that can capture circulating tumour DNA and emit a fluorescent signal, allowing point of care detection with just a blood sample. This is a game-changer in liquid biopsy as we are able to detect cancer in 1-2 hours compared to the 1-2 weeks turnaround of a standard liquid biopsy. We have an AI system to predict cancer progression, which enables us to generate a custom set of nanorobots to capture different biomarkers, enabling personalised treatment.

Panakeia Technologies : Pahini Pandya, CEO

Panakeia makes cancer diagnosis simpler, faster and cheaper by reducing the need for multiple tests. Pathologist assessment of biopsies is the gold standard for cancer diagnosis today. Complete diagnosis requires at least 4 additional tests done in separate labs. This takes 20 days and costs hospitals several thousand pounds. Panakeias' software uses deep-learning to provide pathologists with comprehensive diagnostic information from biopsy images they already have and fits into existing workflow. Patients can get diagnosis in 1 step, 2 days and at a fraction of the cost. We have partnerships with top cancer centres across 3 continents for data and trials of our patent-pending technology.


Antiverse : Rowina Westermeier, Director

Antiverse is developing a disruptive technology to predict antibodies against antigens using machine learning.

FindMeCure Ltd: Ralitsa Vaskova, Executive

FindMeCure is a young tech company with a clinical research background, working in the field of digital patient recruitment. 
Using our own intelligent algorithm, our online platform helps people all over the world find and join the most suitable for them clinical trials and at the same time helps companies to find easier and faster the most suitable patients for their clinical trials. 
We also have developed an Intelligence Data Platform combining real-time data, social listening and our proprietary algorithms to better plan and/or speed up clinical trials.

Quantum on Demand : Gunter Hermann, Co-Founder

Quantum on Demand (QoD) is a simulation-based and AI-driven research platform for the chemical and pharmaceutical industry. Powered by chemical and biochemical prediction models, we help our customers to accelerate the R&D of new pharmaceutical ingredients and novel materials - while increasing the cost-efficiency.

Lyfegen HealthTech AG : Nico Mros, Co-Founder and COO

Lyfegen is a healthcare technology company that has developed a ground-breaking solution to accelerate value-based healthcare. Its platform, Lyfevalue, collects, analyses & reconciles disparate healthcare data for the purpose of automating value-based healthcare contracting. The platform enables life science companies, national and private healthcare payers and healthcare providers to operationalise value-based healthcare strategies whilst benefiting from a single holistic solution for their value-based healthcare operations. In addition, the platform allows for personalised healthcare by enabling patient level pricing, fostering accelerated and facilitated access to innovative treatments for patients. 

Fast BT : Balendu Avvaru, CSO 

Fast BT is developing a revolutionary detection technology to enable the early detection of infectious diseases and biomarkers.


  Causaly : Yiannis Kiachopoulos, CEO 

Causaly is the world’s biggest Evidence Data Platform for BioMedicine. Our AI platform machine-reads 25,000,000 academic biomedical publications, adding 100,000 new publications every month. Within seconds it identifies and visualizes patterns, insights and relationships which leads to: Discoveries and insights from millions of articles that the human brain could easily miss, Better decision-making through improved understanding of patterns and relationships, Time- and cost savings by pre-reading and pre-qualifying millions of articles, Increased confidence in evidence scoping and improved article discovery due to premium content, Causaly is working with Industry, Governments and Academia to enable faster, higher quality and more transparent decision-making based on evidence.

InSilicoTrials Technologies : Luca Emili, CEO 

InSilicoTrials is the first cloud-based platform that provides healthcare companies and researchers with easy-to-use tools to perform computational modeling and simulation in pharmaceutical and medical devices development. We are working with FDA and EMA to make easier the development of new lifescience products

Lab Me Analytics : Anthony Close, CEO

Making Blood Testing Painless
At Home Testing, Simplified Results, & In-App Doctor Consults 
Say Goodbye to Needles and Waiting Rooms

Sens ID : Ronald Vos, BD 

Our products are the ideal solution for your R&D, validation of your instruments, external control, preparation of accreditation, ring trials, conformity assessment, as part of your diagnostic test kit, and much more. We offer you a range of human material in diverse product categories like gDNA, cfDNA/ctDNA, Plasma and FFPE with different genetic modifications like point mutations, insertions, deletions, amplifications and translocations. Additionally, we offer you a range of negative controls (certified DNA free) for liquid biopsy procedures.

Seqera Labs: Evan Floden Co-founder & CSO

We provide solutions to create, deploy and share massively scaleable workflows across clusters and clouds. Founded by the creators of Nextflow, Seqera Labs mission is to foster the adoption of professional open source software and strengthen the community effort around the Nextflow ecosystem. We enable teams to monitor, optimize and deploy pipelines in highly regulated environments, ensuring success at every step, from development to maintenance in production.

Arthronica : Letizia Gionfrida CEO

Arthronica is diagnostic medical tool that assists clinicians in the treatment auto-immune inflammatory conditions, C.R.Os in the running of clinical trials and Pharma companies in proving the effectiveness of their drugs. By utilising cutting edge artificial intelligence and ubiquitous consumer devices (smartphone/laptop) Arthronica provides precise longitudinal data on patients, enabling for first time, truly objective assessment,  treatment and recovery. Arthronica is a spinout company from Imperial College London, has received investment from Entrepreneurs First and Research England, and is a partner at JLabs in Beerse (the only European Johnson & Johnson innovation centre).

Entropica Labs : Tommaso Demarie, CEO

Entropica Labs is a spinoff of Singapore's Centre for Quantum Technologies, building a platform that uses machine learning on classical and quantum computing to analyse complex biological data. Entropica's mission is to generate new actionable biological insights from multi-omics datasets and phenotypic measurements, yielding a more robust drug discovery process to treat complex diseases. The vision is to reimagine how biological systems are simulated in silico, reducing the time and money spent testing and experimenting in the wet lab. The founding team has over 15 years of experience in quantum computing, distributed computing and machine learning

Pharmatrace :

PharmaTrace is a healthcare ecosystem built on blockchain. Leveraging A.I. & Machine Learning to connect complex data and create true digital transformation, we help pharmaceuticals and healthcare entities adopt blockchain technology to secure data, deploy smart contracts and AI/ML which enhance patient lifes hence better outcome- smart data usage, and transforming the medical chain environment.

FaunaBio : Ashley Zehnder Founder CEO

Fauna Bio is pushing beyond the classic mouse model to develop a cross-mammal drug discovery platform that takes advantage of 100 million years of evolution. 
The elephant’s resistance to cancer is a popular example of an animal adaptation that promotes health and longevity, but many others exist. Hibernating mammals begin to develop conditions similar to heart attack, stroke, diabetes, osteoporosis, and Alzheimer’s disease, but unlike humans, they are able to protect themselves from damage, or even subsequently cure themselves of these illnesses. With the recent dramatic drop in sequencing costs thousands of humans are being sequenced, but other mammal species remain an untapped reservoir of information that could be used to inspire therapeutic discovery.

Decentriq : Nikolas Molyndris, Head of Product

Our avato Platform provides the software infrastructure on top of the public cloud to enable organizations to collaborate on, and analyze encrypted data, right from the user’s browser.


Sano Genetics : Patrick Short, CEO

Sano Genetics is a platform for genomic and medical data with privacy and transparency at its core. Using a crowdsourcing model, we provide engaged patient cohorts and data for clinical trials recruitment and drug discovery.

Bio.tx : Marco Schmidt Founder & CEO


FeetMe : Alexis Mathieu CEO 

Smart medical wearables to improve mobility. The most advanced platform for the assessment of gait in real world setting.

Advancience : Christian Vogler CEO

Advancience is a Swiss data science company that develops and applies highly scalable software solutions for the digital measurement of human behaviour and intellectual capacity. We are digitally reinventing the psychological research toolkit: By using entertaining computer games, we derive insights from ultra-large reference cohorts, while simultaneously we’re drastically speeding up the process of generating scientific insights. Our revolutionary data and privacy policy hands full control over personal data back to the citizen who contribute.
We use our next-generation psychometric toolkit and automated advanced statistical analysis to bring digitization into the field of applied psychology in the healthcare sector. Our online-based toolkit can be used to deliver objective markers of cognitive functioning for diagnosing and monitoring of neurological/psychiatric patients and provide digital biomarkers in clinical trials.

Kaiser & Preusse : Martin Preusse CEO

Kaiser & Preusse builds data solutions for research, biotech & pharma. We offer a unique combination: a deep understanding of systems biology, and practical experience in building Neo4j solutions. With our know-how, we cover everything from basic science to drug development and healthcare.

Brainpatch.IO : Alessandro Monterosso CEO

A B2B platform for developing apps for non-invasive brain stimulation using AI. The technology entails simultaneous recording and stimulation of the brain signals using electrodes contacting the scalp. The business model relies on a community of AI developers developing and testing machine learning algorithms for real-time optimisation of stimulation protocol for each application for each individual. The technology will use blockchain-enabled infrastructure for ensuring maximum efficacy, safety and trust in the applications.

CogniScent : Micol De Ruvo CTO

At CogniScent, we develop non invasive testing for early detection of Parkinson’s and Alzheimer’s: using machine learning, we define a personal risk profile based on digital questionnaires and on a smell test. Users have access to a detailed report, together with recommendations and support.

LIVEsciences : Caroline Seidel, Catalyst

LIVEsciences is a team of young and purpose-driven individuals with a passion for unleashing the potential of people by liberating them from limiting structures and processes. Together with our clients we help them find the best combinations of different novel approaches that allow them to become more agile, innovative, and impactful. By developing customized approaches specific for their context and business culture we catalyze sustainable success

LifeBit Solutions : Maria Chatzou CEO

Lifebit is building the world’s first intelligent genomics platform that understands DNA data and generates meaningful insights like humans do. This offers researchers and their corresponding organisations (ie. pharmaceutical) a highly scalable, modular and reproducible system that automates the analysis processes, learns from the data and provides actionable insights.

Visium SA : Alen Arslanagic CEO

Machine Learning product development company developing tailored solutions, specialized in health & pharma and working with numerous top 50 Swiss companies

Predict Care : Markus Mäkelä Co-Founder

PredictCare LLC is building an End-to-End, Predictive & Individualized Patient & Disease Management Platform based on a State of the Art Artificial Intelligence Engine.The platform brings the individual to the center of all actions at the right time and with the right action.The platform serves all stakeholders and gathers data from all sources, even from digital health devices and wearables. Through the wide coverage the platform provides a disruptive approach to predicting the disease and individualizing the care and actions. The first use case for the platform is End Stage Renal Disease. The platform itself is agnostic of any disease.

Allcyte : Berend Snijder Co-founder
Allcyte is a biotech start-up company focused on functional drug testing in primary human material. With our Pharmacoscopy high-content imaging platform, our mission is to bring the next generation of personalized medicine to cancer patients and treating physicians, and support pharmaceutical companies to focus their drug development efforts on the right molecules in the right indications. We enable research through the image-based quantification of single-cell phenotypes - all performed directly in primary patient material with minimal amounts of manipulation and requiring minimal amounts of sample. We integrate these data using cutting edge methods of statistics and machine learning to generate actionable insights for our customers. Our mission is to help you make the best possible biomedical decisions.

Nocturne GmbH : Ella Maria Kadas CEO

We at Nocturne specialize in products and services that allow diagnosing and monitoring neurologic disorders through imaging of the eye. Nocturne’s proprietary technology (patent pending) analyses 3D images of the retina, which are obtained by optical coherence tomography (OCT). With its service Nocturne addresses customers in pharmaceutical research, academia, and clinical care. Currently our main focus is multiple sclerosis, with future applications in Parkinson’s and Alzheimer’s disease. Our goal is to improve accuracy of the initial diagnosis and to provide a close disease monitoring for initiating the right treatment and treatment adjustment, with the possibility of reducing the number of costly and time consuming MRI examinations.

InVivo AI : Daniel Cohen, CEO

Founded in January 2018, InVivo AI is developing novel algorithms for low data drug discovery, providing us the unique ability to work with the small and noisy datasets characteristic of early-stage drug discovery. Through close collaboration with strategic partners, we combine proprietary disease models with our computational discovery engine to design and optimize novel drug candidates, with an initial focus on complex targets in oncology and CNS.

SwissVault Systems : Bhupinder Bhullar, CEO

Swiss Vault makes compute and data storage platforms for the AI market. Our USP is easy to use and deploy desktop AI units, to manage and analyze BIG DATA as it is captured in the field.

BigOmics Analytics : Murodzhon Akhmedov CEO

Data analytics has become the biggest bottleneck in life science R&D. BigOmics solves the big data analytics problem by bringing easy-to-use omics data analytics to the desktop. Our goal is to create a self-service analytics platform that empowers biologists to analyze their data themselves in order get their analysis faster, better and cheaper. BigOmics wants to become the leader in visual omics analytics, the Tableau of omics data. BigOmics Analytics is a spin-off of the University of Lugano and the Institute of Oncology Research.

Intelliseq : Michał Delijewski Business Development Manager

Intelliseq is a dynamically growing biomedical company specializing in the fields of genomics and bioinformatics. Our mission is to accelerate the medical diagnostics by delivering a simple drop-in software solution for genome analysis. We are launching an automatic genome interpretation system that creates clinical reports and easily integrates with laboratory information systems. We aim to enhance people’s lives through a translation of genetics knowledge into meaningful medical insights. Our drop-in solution fits all NGS analysis approach: from a single gene to a whole genome, for genetic diseases, hereditary cancer, carrier screening, pharmacogenetics and genome-wide association study. It enables to access genome-based diagnostics and precision medicine.

Axom : Tristan Salomon CEO

We are supporting companies by helping them to integrate artificial intelligence into their processes. We define, realize the implementation and support the operations.

TagBio : Tom Covington CEO


Pangaea : Vibhor Gupta CEO

Pangaea provides a machine learning based software product to its customers from the Biopharmaceutical industry for faster identification of patient cohorts based on phenotypes (clinical characteristics) from electronic health record (EHR) data, which is critical for drug discovery, clinical trials and early diagnosis in the context of precision medicine. Pangaea’s approach is proven to be at least 50 times faster and 20% more accurate than alternative technical approaches which do not use machine learning and rely only on natural language processing (NLP) or keyword mapping between EHR data and terms such as ICD and SNOMED codes. Pangaea’s technology is based on the founders’ work over the last 20 years in industry and at Imperial College London and Stanford University. The company was founded in London by experienced founders, who have secured $250 million through their work over the last decade, which included two successful exits. Pangaea is advised by renowned scientific and technical experts from the Biopharmaceutical domain and based in the UK and San Francisco.

Exeon Analytics : Carola Hug COO

Our flagship product ExeonTrace uses machine learning and clustering algorithms to understand the activities in your corporate network and to identify and investigate malware infections and data breaches. ExeonTrace is easy and light-weight to deploy, as it analyzes existing network and event log data that can be loaded from Splunk, Elasticsearch or raw files.

Lunaphore : Andrea Buchler BDM

Lunaphore brings critical innovation in tissue analytics based on a breakthrough microfluidic technology. Lunaphore Solution is a complete tissue processing platform which can automate the most sophisticated tests used in cancer research (such as highly multiplexed immunofluorescence or in-situ sequencing), perform those assays up to 20x faster and enable direct digitalization for sequential data extraction.

Knowing01  : Nikola Müller CEO

Science generates big data, yet knowledge still grows slowly. Knowing Health software builds on our intelligent cell map technology to store and automatically connect virtually any type of biomedical data. With easy-to-use and easy-to-understand products, our customers quickly unbury the treasures hidden in big datasets. We are helping you to increase the quality of your data-derived findings and actions! Ultimately, we accelerate drug development and therapies.

InterVenn : Daniel Serie, Head of Computational Biology

InterVenn couples the power of mass spectrometry with AI-based signal processing to quantify site-specific protein glycosylation at a platform scale. The measurement of specific glycoforms provides unique insight into protein functionality that traditional immunoassays or aptamer-based approaches cannot. Aberrant glycosylation is implicated in all manner of diseases, and our platform enables researchers to investigate this little-studied layer of biology. InterVenn’s proprietary Artificial Intelligence enabled workflow massively accelerates turnaround time and increases analytical reliability of historically unruly mass spec data, opening up new avenues for clinical diagnostics and companion diagnostics.


Dicronis GmbH : Jovan Jancev, Co-Founder and CTO

​The first product in our pipeline, Lymphit, enables the quantitative assessment of the lymphatic function of the patient in a safe, home-based and highly scalable manner. The initial indication of Lymphit is the earliest possible diagnosis of secondary lymphedema, a serious side effect of many cancer therapies. By remotely monitoring the lymphatic function, the doctor is empowered for the first time to perform an early diagnosis, before any swelling of a limb has occurred, and timely prescribe the best conservative treatment for the patient. This leads to a great improvement of the prognosis and quality of life of the patient and important savings for the healthcare system and society.

PharmaBiome : Marco Meola, Head of Data Sciences

PharmaBiome pioneers next-generation microbiome therapies. Our bacterial mixes target functional disbalances of the microbiome – an underlying cause of incurable diseases such as ulcerative colitis. Our portfolio of previously uncultured intestinal bacteria and our proprietary technology allow greater control over production, storage and therapeutic efficacy. The scalability and versatility of our process allows the fast development of a diversified compound portfolio

SDS OPTIC Mateusz Sagan CBO

SDS Optic Inc., HQ in Lublin, Poland, is a cutting-edge HealthTech specializing in connecting vast molecular biology & medical knowledge with technical skills to create solutions that can revolutionize healthcare worldwide.Our strategy is to discover, develop and commercialize disruptive diagnostics and monitoring tools on a global scale and create lifesaving innovations which can help medical professionals in real-time and increase patients well-being. Our vision is to help increase cancer survival by 30% by 2030 and co-create the future of fighting cancer with implementing real-time, in vivo and numerical based personalized diagnostics & monitoring inPROBE platform technology.

Arctoris Ltd : Thomas Fleming Co-Founder & COO

Arctoris is the world's first robotic laboratory for drug discovery, offering a powerful platform for low cost, high quality in vitro assay screening. Accessible remotely, the platform enables pharma, biotech and academia to configure, run and monitor experiments in real-time, enabling rapid, informed decision-making in basic biology, target validation, toxicology and phenotypic screening. Combining the latest in cellular and molecular techniques, and in instrumentation with machine learning analytics, Arctoris puts the most powerful research capabilities at scientists' fingertips.


Dotphoton :   Michael Desert VP Sales

Make your biomedical imaging system ready for AI and remote image processing. Most of existing imaging systems deliver lossy image quality, whilst pathologists and scientists wish to improve image analysis with post-processing tools that require artifact-free raw images were the tradeoff is big file size. Dotphoton’s validated and patented image optimization algorithms provide reliable image data for AI that allow you to improve biomedical imaging systems performance, to make the end-user’s life easier by offering manageable data volume and by delivering images compatible with all existing image processing algorithms and future Artificial Intelligence and Machine Learning algorithms.


Genomtec : Miron Tokarski CEO

Genomtec develops smartphone-size genetic analyser for infection detection in doctor's office in less than 15 minutes. Genomtec ID device utilises patent-pending, contactless photon-based heating and detection technology for simultaneous detection of up to 5 pathogens from a single sample with innovative isothermal amplification technology. The test procedure is simple - it requires sample e.g. throat swab or urine to be applied on the microfluidic card. All analytical processes – nucleic acid extraction, purification and concentration as well as amplification and semiquantitative detection are performed automatically. The system can detect bacteria, viruses, fungi as well as DNA mutations necessary for companion diagnostic.



Denapsis Artificial Intelligence : Behrooz Torabi, CEO

Denapsis Artificial Intelligence was founded in April 2018 in Uppsala, Sweden, by a team of visionaries having years of experience in industry and academia. The main expertise we bring to the table are:Artificial Intelligence and Machine learning, Complex algorithm development, Software development, Advanced data analysis and modelling, Image and signal processing
Moreover, we have worked with multi -omics data sets and we speak the language of researchers and specialists in Life Science.
We develop proprietary solutions with no dependencies on 3rd party products, since we are convinced that our customers are best served by individual, customized, solutions. All IP remains with our customers, giving them a critical advantage over competitors.


Merakoi : Silja Chouquet, CEO

Merakoi’s global network of patient experts enables healthcare companies to create patient-beneficial solutions.


HitFoundation : Eberhard Scheuer Founder​  

HIT Foundation is a decentralized health information infrastructure to support consensual data sharing between individuals and organizations. Due to blockchain-technology, the HIT Foundation's platform does not store user data for match-making. A community-owned exchange tokenizes the value of health information. The embedded reward system enables individuals to pay for health services with their data..


Apheris : Robin Roehm, CEO Co-Founder 

At apheris AI we are building a platform for federated and privacy-preserving analytics & AI for biomedical data. We empower companies to train secure models and gain insights from distributed data sets while protecting the privacy of data during the analysis or training. In particular, we enable companies to securely exchange data and data insights between and within institutions. For example, we enable biomedical companies to run computations on other companies’ proprietary data, while never actually seeing the data itself and thereby protecting sensitive patients’ and other data.


Haut.AI : Anastasia Georgievskaya, CEO 

Haut.AI is an Estonian startup developing AI algorithms for recognition of skin pathologies. Our developments are based on the algorithms of computer vision and machine learning including deep learning. Our core product is SaaS for skincare..


Brainomix : Jeff Wyrtzen, BDM Director 

We create AI-driven software designed to maximise the value of simple brain imaging, helping physicians make life-saving stroke treatment accessible to all patients. Since launching as a spin-out from the University of Oxford in 2010, our award-winning, CE-marked solutions have been validated in over 20 peer-reviewed publications, and have been used in over 300 hospitals across 25 countries. Our e-Stroke Suite platform is improving stroke patient outcomes by delivering the diagnostic confidence necessary to make therapeutic decisions in just a few minutes.


BowheadHealth : Sofia Diaz, Project Manager

Bowhead Health helps users own and manage their behavior health data to better understand themselves and contribute their health data to medical research. In turn, the platform allows researchers or healthcare companies to access a large number of people with specific conditions or diseases in a secure real world data sharing environment. Data visualization enables platform users to understand gaps in management or healthcare access and to develop strategies to launch new treatments.


Nutrasim : Tan Rasab CEO

One size does not fit all; one man's food is another man's poison. Cliches aside, it has been proven that personalized diet, medicine and therapies are much more effective than the standardized, generic “one size fits all” approach. 
We are a Cambridge (UK) based startup focusing on building a globally scalable streamlined standardised targeted genomic profiling process and analysis combined with a proprietary cognitive analytics platform to deliver the world’s most advanced insight and intervention for people suffering from chronic illnesses to help them lead healthier and happier lives. 
We are primarily focusing on building the necessary infrastructure and services for lower income areas and developing countries for personalised intervention and therapies. 
Our services will assist people with a range of nutritional related illnesses such as obesity, cardiovascular diseases, and diabetes.


Dopavision : Tim Schilling, Vision Scientist

Myopia, or shortsightedness, is a condition where the visual image is focused in front of the retina, instead of on the retina itself, as it should. People with myopia have good near sight vision but poor distance vision. Dopavision is developing a digital therapeutic for myopia which can be seamlessly and invisibly integrated with the use of a smartphone. Myopia is a visual condition that affects on average every third person globally, a share that has increased rapidly during the last two decades. It has grown to alarming proportions in Asia where prevalence rates, e.g., in Singapore, have reached 80% among young adults. High myopia imposes a significant risk to cause visual impairment and even blindness later in life.
The goal of the Berlin-based startup is to develop a clinically validated therapy for myopiaprogression in children and adolescents. The technology delivers light stimulation to specific photosensitive cells on the retina which in turn modulate dopamine, a neurotransmitter that is important for the regulation of eye growth. Founded in 2017, Dopavision GmbH is supported by the German government via the “Industrie-in-Klinik” program of the BMBF (Federal Ministry of Education and Research) with the amount of € 1.4 million over three years. Additionally, the company is backed with venture capital in a seed round to advance the research and further develop the product for clinical validation.


ChemOS Inc: Loïc Roch, CEO 

ChemOS Inc. is an AI software startup; the Chemical Operating System for Industry 4.0. Our technology accelerates innovation and makes process optimization and materials discovery better, faster, and cheaper. The ChemOS platform fully integrates AI, machine learning, high-performance computing and robotics with natural sciences. Our software can operate with limited data, with or without robots, or in computer simulations. It currently outperforms state-of-the-art methodologies (DoE and HTE) by up to 34x.


Healios : Guilhem Dupont, President & CEO

We are mostly interested in contributing to the new era of data for healthcare and in particular in contributing to the development and broad usage of digital biomarkers and digital therapeutics in neuroscience.


Precordior Ltd : Juuso Blomster, Chief Executive Officer


GeneLook AG : Daniel Gutierrez, Co-Founder & CEO 

GeneLook is the mobile app that allows individuals to seamlessly interact with their DNA code. GeneLook has developed the DNA Alert System, a platform that alerts its users of newly discovered genetic variants of risks, that may be detrimental to the health of those that carry the mutation. 
GeneLook empowers this individuals to privately share such sensitive information with the healthcare ecosystem to find (or develop) a cure or a treatment or even to enrole in a clinical trial, while the rest of the DNA code of the user remains undisclosed and protected.   
GeneLook is advancing the state of the art in individualized genomics and insight into health and disease prevention. Accelerating pace of development in genomics insights and DNA sequencing tools has enabled increasing access to the technology.  The GeneLook platform empowers consumers to be in full control of their DNA code and to obtain personalized value-based healthcare to their unmet needs. In addition, the GeneLook marketplace enables research & development to advance understanding of various disease outcomes through data sharing.
At its early stage, GeneLook focuses on rare disease patients as they have a clear unmet need. GeneLook has successfully consolidated a synergy with two important players of the healthcare ecosystem and is working on a solution for a specific rare disease community as its first milestone.   


Self Care Catalyst : Grace Castillo-Soyao Founder, Chief Innovation & Strategy Officer

Self Care Catalysts (SCC) is a digital  therapeutics, research and analytics company that enables patient engagement and personalized care through its disease agnostic, highly-customizable and personalizable Health Storylines software platform. SCC's platform enables research to be conducted throughout the drug development life cycle, ensuring patients remain the center of clinical practice and research. Self Care Catalysts operates at the intersection of human networks, technology and science, leveraging real world data, alongside biomedical research through the patient journey to inform and impact care, outcomes and payment decisions.


Leitwert GmbH : Miro Käch, CEO 

We help clients solve the challenges of integrating and managing wearable devices in clinical trials.
Our solution manages the data flow from any device within and outside of clinics to any IT system, while automatically monitoring participant compliance and the plausibility of incoming data. Clinical professionals can remotely manage device settings and check its status.
These functionalities enable the acquisition of data from patients during every-day life, which is extremely relevant to develop and validate personalized treatments in long term studies, boost participant retention, comply with regulatory requirements for post-market surveillance and manage chronic diseases.


Autreen : Faraz Oloumi, Founder,Director

Aurteen develops a machine-learning-based platform for the automated detection of various disorders by analyzing images from the back of the eye. First applications deal with retinopathy of prematurity and diabetic retinopathy, two of leading causes of blindness among children and adults, respectively. Aurteen is currently extending its platform to include assessment of glaucoma and macular degeneration. The company will also start to tackle the use of the MI-based systems for cardiovascular & neurodegenerative applications in the near future. 
Aurteen's vision is to have yearly retinal exams done on every person to provide a snapshot of their health status and assist with proactive preventative health-care measures. This can be achieved with a few digital images taken by a family doctor, optometrist, or a service offered in public spaces, similar to blood pressure screening in pharmacies. Images are rapidly processed and analyzed off-site by Aurteen’s software. A report is provided to the patient, as well as their doctor, listing concerns found through the analysis of retinal images. Subsequently, the patient/doctor will be able to initiate disease prevention and/or treatment plans.
Aurteen’s main business is to provide assessment/diagnostic services that can be used by teleophthalmology-service providers, optometrists as well as the general public to generate automated assessments of the retina and overall health. Services will run through Aurteen’s servers and be charged on a fee-per-image basis.


Bioreperia : Larissa Rizzo, MSL

BioReperia is a Swedish company founded in 2015 by two researchers from Linkoping University with the vision to reduce cancer mortality by identifying the moste efficient treatment for each specific cancer patient and improve the cost effectiviness of modern anti-cancer therapies.
BioReperia have developed a platform to stratify patients who would benefit of targeted cancer treatment within 5 days instead of a cancer treatment cycle of 6-12  months. Using a cost-efficient individulized cancer treatment will reduce cancer mortality, decrease cost for healthcare, and be a great benefit for patient.
Our platform provides an analysis that predicts the most efficient cancer drug for individual patients within 5 days of surgery/diagnosis, which is more accurate, faster and cheaper than other technologies available. By providing an analysis of individualized responses to anti-cancer  therapies, together with genomic and other patient data, we further aim to provide a cloud algorithm, which will improve the cost-effectiveness and prediction of modern anti-cancer therapies. 
We are already on the market within pharma industry as service providers to accelerate drug discovery. Our product ZTX-ONCOLEADS for drug discovery is already on the market in the Nordics and in Switzerland


Genomebiologics : Jonathan Ward, CEO and Co-Founder 

Genome Biologics identifies pipeline drugs and repositions FDA approved compounds for Cardiovascular and Cardiometabolic Rare Disease. Capitalising on the power of our patented Artificial Intelligence (AI) driven preclinical multi-modality drug testing technology, we leverage the power of AI-based machine learning with transformative patient-derived tissue screens and in vitro and in vivo transgenesis to dramatically reduce the cost, time and inefficiencies of preclinical research.


Mimamsia UG : Shivendra Kishore Founder and Managing Director

Mimamsia pursues a global cross-sector approach to overcome barriers to diagnosis and therapy by directly engaging and empowering Rare Disease patients to seek active solutions towards driving innovation in diagnostics and therapeutics. Our particular focus is on the undiagnosed or “yet to be diagnosed” patients where we utilize advanced “personalized” algorithms to increase diagnostic efficiency from Whole Exome/Genome Data. For all patients, diagnosed or undiagnosed, we are developing a portable medical data “vault” where individual medical data is fully owned, controlled and transacted by patients to proactively promote rapid and safe information exchange among multiple healthcare sectors that aim to improve patient outcomes.



ImmunoDigital: Sebastian Stolzenberg, CEO

Our artificial intelligence software predicts the immunogenicity of proteins with applications in drug discovery and vaccine development..


Remisso : Stefan van Rest, CTO

We develop immunotherapies using artificial intelligence.


Gnosis Data Analysis PC : Ioannis Tsamardinos, CEO

Gnosis Data Analysis is an exciting, energetic, enthusiastic start-up company working on AutoML products and advanced machine learning consulting services. Gnosis is a University of Crete start-up with partners in Greece, Denmark, Germany, and Georgia


Genexa AG : Michael Schmid, Founder and CEO

Genexa is a provider of genomic data analysis based in Zurich, Switzerland. Our bioinformatics services focus on the analysis of genomic and metagenomic data. Our services can be either "raw data" driven (for example genome assembly or profiling of metagenomes) or "big data" driven. As an example of "big data" driven projects, we are currently working with a biotech start-up where we perform important bioinformatics analyses by analysing large amounts of publicly available data. The results of our analysis are essential for the development of the company's core product.



Bioinformatics.Expert UG: Felix Bormann, CEO

Big data becomes more important in life sciences but also more challenging. This is mostly not due to missing programmatic routines for the analysis but due to missing access, know-how and infrastructure to these resources. Found in 2018, Bioinformatics.Expert UG can offer anyone who is interested to perform bioinformatic analyses the right products for their needs as well as the necessary computational infrastructure. Those include but are not limited to RNAseq-, ATACseq-, ChipSeq-analyses, analyses of Microarray-data but also simple PCA, t-SNE or even Heatmaps. Additionally, Bioinformatics.Expert UG can offer instruments to ensure bioinformatic reproducibility throughout different analyses.


Nostos Genomics : David Gorgan, Co-Founder & CEO

Nostos Genomics developed a platform for AI-driven deciphering of genetic diseases. It leverages a combination of machine learning and synthetic biology to characterise the impact of genetic variants at scale and use this data to improve the diagnosis and treatment of rare genetic diseases.


Contact us

To sponsor or exhibit contact:
Alistair Wilmot
+44 (0)207 092 1174

To speak:
Chris Shanks
+44 (0)207 092 1151